UK-US pharma deal deepens neoliberal healthcare commodification, prioritising corporate profit over public health access globally

Indigenous and traditional medicine systems, such as those in Latin America (e.g., Amazonian plant-based remedies) or Africa (e.g., Swahili unani medicine), offer low-cost, culturally adapted healthcare solutions but are systematically excluded from global health policy frameworks. These systems often operate outside patent regimes, making them incompatible with neoliberal trade deals that prioritise corporate IP. The UK-US pharma deal further marginalises these alternatives by reinforcing a biomedical monopoly, despite their proven efficacy in treating chronic and infectious diseases.

The deal echoes colonial-era pharmaceutical exploitation, where European powers extracted medicinal knowledge from colonised regions (e.g., quinine from South America, morphine from the Ottoman Empire) without fair compensation or benefit-sharing. Post-colonial trade agreements, from the TRIPS Agreement (1995) to US bilateral deals, have systematically dismantled the ability of Global South nations to produce affordable generics, as seen in South Africa’s HIV crisis and Brazil’s patent battles. The UK-US deal continues this legacy by locking in corporate control over essential medicines.

Non-Western healthcare models, such as China’s 'barefoot doctor' initiative or Thailand’s 30-baht healthcare scheme, demonstrate that universal access is achievable without corporate monopolies. The deal’s focus on tariff-free access for British medicines ignores how Global South nations could benefit from technology transfer or joint ventures with local producers, as seen in India’s vaccine diplomacy. Instead, it reinforces a one-size-fits-all approach that privileges Western pharmaceutical giants over diverse, community-based healthcare systems.

Pharmaceutical innovation is often driven by publicly funded research (e.g., NIH in the US, MRC in the UK), yet corporate monopolies via patents allow private firms to extract rents without reinvesting in R&D for neglected diseases. Studies show that patent extensions (e.g., via trade deals) correlate with higher drug prices and reduced access, particularly for cancer and HIV treatments in low-income settings. The deal’s emphasis on 'tariff-free access' ignores the far greater barriers posed by patent monopolies, which account for 80% of the cost of new medicines.

Artistic and spiritual traditions often frame health as a collective responsibility, not an individual commodity, as seen in African ubuntu philosophy ('I am because we are') or Buddhist concepts of interdependence. These frameworks challenge the transactional nature of Western healthcare, where access is determined by purchasing power rather than need. The UK-US deal further entrenches a materialist view of health, erasing the role of community care, ritual healing, and holistic wellness practices that have sustained societies for millennia.

If unchecked, this deal could accelerate a two-tier global healthcare system, where wealthy nations enjoy subsidised access to cutting-edge drugs while low-income countries face prohibitive costs, exacerbating health inequities. Scenario modelling suggests that by 2035, patent-driven price hikes could lead to 10 million preventable deaths annually in Africa and South Asia, as generic alternatives become unaffordable. Alternative futures, such as open-source drug development or pooled procurement models, are systematically sidelined by such agreements.

Marginalised communities—particularly in the Global South, indigenous groups, and low-income populations in the UK—are the most affected by this deal but have no seat at the negotiating table. Public health advocates, such as Médecins Sans Frontières (MSF), have repeatedly warned that trade deals prioritise corporate profits over patient needs, yet their voices are excluded from mainstream narratives. The deal also ignores the disproportionate impact on women and people of colour, who bear the brunt of healthcare inequities but are rarely consulted in policy decisions.